Fatemeh Afra

Fatemeh Afra

Auto-generated profile, based on publicly available information

Fatemeh Afra

Network of Interdisciplinarity in Neonates and Infants (NINI) Universal Scientific Education and Research Network (USERN) Tehran Iran

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2025 in Health Science Reports
Verified
Journal Article
Open access
SKSoroush Khojasteh‐Kaffash
Soroush Khojasteh‐Kaffash
AHAdrina Habibzadeh
Adrina Habibzadeh
SMSina Moghaddam
Sina Moghaddam
FAFatemeh Afra
Fatemeh Afra
NSNoosha Samieefar
Noosha Samieefar
AFAbolfazl Fateh
Abolfazl Fateh
Background and Aims: Tuberculosis (TB), a leading cause of death from infectious diseases, faced considerable challenges during the coronavirus disease 2019 (COVID‐19) pandemic. This review examines the impact of pandemic‐related disruptions, including the diversion of healthcare resources, reduced access to TB diagnostics and treatment, and declining BCG vaccination rates, on TB trends. The aim is to forecast the post‐COVID‐19 TB burden, identify risk factors that exacerbate transmission, and propose strategies to prevent a global resurgence. Methods: This narrative review incorporates epidemiological data, modeling research, and reports from the World Health Organization and national health systems. It examines TB trends before and after COVID‐19, the outcomes of coinfection, and the pandemic's impact on immunology, socioeconomic factors, and health systems. The review also compares trends in India and South Africa—two countries facing significant challenges—to those observed during the COVID‐19 pandemic. Results: COVID‐19 disruptions in healthcare led to an 18% decrease in TB notifications in 2020, resulting in delayed diagnoses, increased household transmission, and higher mortality. Immune dysregulation, including T‐cell depletion and cytokine storms, contributed to a 12.3% mortality rate in COVID‐19‐TB coinfections. Models predict a 5%–15% rise in TB incidence and an additional 1.4 million deaths by 2025. Individuals with HIV, diabetes, and malnutrition were particularly vulnerable. Factors such as overcrowding, air pollution, and reduced Bacillus Calmette–Guérin (BCG) coverage in endemic regions have further heightened susceptibility to TB. Conclusion: COVID‐19 has undone years of progress in TB control, highlighting the need for a unified health strategy. Early diagnosis, treatment of latent TB, and BCG catch‐up initiatives are crucial. Strengthening health systems, addressing socioeconomic factors such as poverty and hunger, and utilizing pandemic advancements like telemedicine and vaccine research will be key to preventing a resurgence of TB. Continued financial support and international cooperation are essential to eliminating TB by 2030.

23 September 2023 in Journal of Cardiovascular and Thoracic Research
Verified
Journal Article
Open access
PDF file
FAFatemeh Afra
Fatemeh Afra
AZArman Zargaran
Arman Zargaran
NSNooshin Shirzad
Nooshin Shirzad
MHMahboobeh Hemmatabadi
Mahboobeh Hemmatabadi
MEMahbube Ebrahimpur
Mahbube Ebrahimpur
SNSoha Namazi
Soha Namazi
Introduction: The internal septum of J.regia is traditionally used to control diabetes, and its effectiveness has been shown in animal studies. Accordingly, human clinical trials are needed to confirm its effectiveness on hemoglobin A1c (HbA1c), fasting blood sugar (FBS), blood insulin level, and insulin resistance as a complementary for better control of type 2 diabetes. Methods: This study was a randomized, double-blinded, controlled trial. The lyophilized powder of extract of the internal septum of J.regia was used to fill the capsules. Sixty type 2 diabetic patients were randomly divided into two groups. 500 mg capsules three times daily before meal was added to their routine drug regimen, and HbA1c, FBS, and blood insulin level were checked at the baseline and after three months. Results: Sixty patients completed the study. The mean(±SD) age of patients was 49.1(10.2) and 50.9(12.7) years in the placebo and J.regia groups, respectively. We observed that J.regia internal septum increases the level of HbA1c by about 0.02 units, but this effect was not significant (MD=0.02,95%CI=-0.36 to 0.40, P=0.93). Regarding the impact of capsules on insulin level, it seems that J.regia-containing capsules can raise insulin level by one unit. However, it was not significant (MD=1.01,95%CI=-0.86 to 2.88, P=0.28). As for FBS, it can cause a decrease of four units, but this effect is also not significant (MD=-3.98,95%CI=-18.33 to 10.37, P=0.58). Conclusion: Based on our study, the internal septum of J.regia has no significant effect on HbA1c, FBS, and insulin resistance. Moreover, no specific adverse reaction was observed in any of the patients.

7 March 2025 in Clinical Case Reports
Verified
Journal Article
Open access
FAFatemeh Afra
Fatemeh Afra
MRMohammad Rahimi
Mohammad Rahimi
MHMahboobeh Hemmatabadi
Mahboobeh Hemmatabadi
SMSomayeh Mohammadi
Somayeh Mohammadi
NSNooshin Shirzad
Nooshin Shirzad
Pheochromocytoma is a rare, primarily benign tumor that arises from the chromaffin cells of the adrenal medulla. It is known for causing excessive secretion of catecholamines, such as epinephrine and norepinephrine. This condition poses significant health risks due to its potential to cause severe cardiovascular complications, including hypertension, stroke, and various forms of cardiomyopathy. A 29‐year‐old woman with a history of diabetes mellitus (DM) and hypertension presented with symptoms suggestive of an infection related to an intrauterine device (IUD). However, persistent symptoms following the removal of the IUD and further diagnostic evaluations revealed dilated cardiomyopathy (DCM) secondary to catecholamine excess, which led to the diagnosis of pheochromocytoma. This diagnosis was confirmed through comprehensive laboratory testing and imaging. The surgical removal of the tumor resulted in significant improvement in her cardiac function and the resolution of both hypertension and DM. This case highlights the importance of considering pheochromocytoma in the differential diagnosis of unexplained cardiac symptoms, particularly in young patients with hypertension. The varied clinical presentation can complicate the diagnosis; however, early detection and appropriate management, including surgery, can lead to complete recovery. This case also underscores the potentially reversible nature of catecholamine‐induced cardiomyopathy when the underlying tumor is treated effectively.

29 October 2026 in Clinical Case Reports
Verified
Journal Article
Open access
MGMahshad Ghoddusi
Mahshad Ghoddusi
KSKhashayar Shahverdi
Khashayar Shahverdi
NZNegar Zareshahi
Negar Zareshahi
ZSZahra Shafizadeh
Zahra Shafizadeh
MTMohammad Taghi Talebian
Mohammad Taghi Talebian
FAFatemeh Afra
Fatemeh Afra
Adipsic hypernatremia is a rare disorder characterized by impaired thirst perception despite severe hyperosmolality, most commonly resulting from hypothalamic dysfunction. Hyperosmolar hyperglycemic state (HHS) may further aggravate dehydration and electrolyte imbalance, increasing the risk of neurologic injury, acute kidney injury (AKI), and thromboembolic complications. Reports describing the coexistence of adipsic hypernatremia, HHS, and extensive venous thromboembolism are limited. A 42‐year‐old man with poorly controlled diabetes and recent traumatic brain injury presented with neurologic decline, severe dehydration without thirst, severe hypernatremia, HHS, and transient renal dysfunction consistent with prerenal injury. Persistent severe hypernatremia despite improvement in hyperglycemia, together with preserved urinary concentrating ability, supported adipsic hypernatremia. Further evaluation revealed extensive deep vein thrombosis (DVT) and bilateral pulmonary embolism (PE), while brain imaging showed only mild diffuse cerebral atrophy. The patient was treated with controlled volume and free‐water replacement, intravenous insulin therapy, anticoagulation, and close monitoring of serum sodium, glucose, renal function, and urine output. Gradual correction of hypernatremia resulted in significant improvement in neurologic manifestations, renal function, and metabolic abnormalities. Following stabilization, he was discharged on apixaban therapy with scheduled oral hydration instructions and outpatient follow‐up. This case highlights a possible synergistic interaction between adipsic hypernatremia and HHS, which may have contributed to severe hyperosmolar stress and extensive thromboembolic complications. Adipsic hypernatremia should be considered in patients with severe hypernatremia and absent thirst sensation, particularly after traumatic brain injury, even when neuroimaging findings are unremarkable.

3 November 2026 in Therapeutic Advances in Drug Safety
Verified
Journal Article
Open access
KSKhashayar Shahverdi
Khashayar Shahverdi
MGMahshad Ghoddusi
Mahshad Ghoddusi
ZSZahra Shafizadeh
Zahra Shafizadeh
FAFatemeh Afra
Fatemeh Afra
Statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase to reduce cholesterol but can cause muscle-related side effects. A rare severe form, immune-mediated necrotizing myopathy (IMNM), is an autoimmune condition characterized by proximal weakness, very high creatine kinase (CK) levels, and muscle necrosis with minimal inflammation. We report a 73-year-old man on long-term rosuvastatin who developed acute proximal muscle weakness, dark urine, and acute kidney injury (AKI) shortly after receiving goserelin. Laboratory tests showed severe rhabdomyolysis with markedly elevated CK and renal failure requiring hemodialysis. Muscle biopsy and serology confirmed anti-HMG-CoA reductase (anti-HMGCR) IMNM with complement-mediated muscle injury. Treatment with high-dose corticosteroids led to gradual improvement in strength, although residual renal impairment persisted at discharge. We describe a rare presentation of anti-HMGCR IMNM with fulminant rhabdomyolysis temporally associated with initiation of goserelin in a patient on chronic rosuvastatin therapy. The findings raise the possibility that gonadotropin-releasing hormone (GnRH) agonists may act as additional immunomodulatory triggers in genetically or immunologically predisposed individuals. Early recognition and prompt immunosuppressive treatment are essential to prevent irreversible organ damage and improve outcomes.